Contrasting Mosaic ImmunoEngineering (OTCMKTS:CPMV) and Repligen (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) and Mosaic ImmunoEngineering (OTCMKTS:CPMV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Volatility and Risk

Repligen has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Mosaic ImmunoEngineering has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500.

Valuation & Earnings

This table compares Repligen and Mosaic ImmunoEngineering”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$638.76 million	12.80	$41.58 million	$0.25	583.74
Mosaic ImmunoEngineering	N/A	N/A	-$1.01 million	($0.13)	-6.91

Repligen has higher revenue and earnings than Mosaic ImmunoEngineering. Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Repligen and Mosaic ImmunoEngineering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Repligen	-0.32%	3.36%	2.41%
Mosaic ImmunoEngineering	N/A	N/A	-870.03%

Insider & Institutional Ownership

97.6% of Repligen shares are held by institutional investors. 1.2% of Repligen shares are held by insiders. Comparatively, 81.0% of Mosaic ImmunoEngineering shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Repligen and Mosaic ImmunoEngineering, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0	2	8	0	2.80
Mosaic ImmunoEngineering	0	0	0	0	N/A

Repligen presently has a consensus target price of $190.25, indicating a potential upside of 30.37%. Given Repligen’s higher possible upside, analysts clearly believe Repligen is more favorable than Mosaic ImmunoEngineering.

Summary

Repligen beats Mosaic ImmunoEngineering on 9 of the 11 factors compared between the two stocks.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.